Pharma Leaders Fireside Chat

Time: 9:00 am
day: Day Two


  • Highlighting the synergies between cell-based therapies and vaccines to create a common framework for development
  • Sharing thoughts on how the intrinsic service component in the commercialisation of neoantigen therapies requires similar patient preparation, additional treatment, follow up, and a specialised workforce and how these fit into the ‘big pharma’ model
  • Identifying opportunities for shared collaboration across different pipelines and creating an outline to develop pipelines with a common thread across the industry to facilitate collaborations, mergers, and acquisitions